research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
2 parts bai zhi (Chinese:白芷，Angelica dahurica); 2 parts cao wu (Chinese:草烏，Aconitum sp., monkshood or wolfsbane); 2 parts chuān ban xia (Pinellia ternata); 2 parts chuān xiōng (Ligusticum wallichii, Cnidium rhizome, Cnidium officinale or Szechuan lovage); 2 parts dong quai (Angelica sinensis or female ginseng); 1 part tian nan xing (Arisaema rhizomatum or cobra lily) 8 parts yang jin hua (Datura stramonium, Korean morning glory, thorn apple, jimson weed, devil's trumpet, stinkweed, or locoweed). The active ingredients in tsūsensan are scopolamine, hyoscyamine, atropine, aconitine and angelicotoxin. When consumed in sufficient quantity, tsūsensan produces a state of general anesthesia and skeletal muscle paralysis. Shutei Nakagawa (1773–1850), a close friend of Hanaoka, wrote a small pamphlet titled "Mayaku-ko" ("narcotic powder") in 1796. Although the original manuscript was lost in a fire in 1867, this brochure described the current state of Hanaoka's research on general anesthesia. On 13 October 1804, Hanaoka performed a partial mastectomy for breast cancer on a 60-year-old woman named Kan Aiya, using tsūsensan as a general anaesthetic. This is generally regarded today as the first reliable documentation of an operation to be performed under general anesthesia. Hanaoka went on to perform many operations using tsūsensan, including resection of malignant tumors, extraction of bladder stones, and extremity amputations. Before his death in 1835, Hanaoka performed more than 150 operations for breast cancer.
=== Early years: Frankfurt === Theodor W. Adorno was born as Theodor Ludwig Wiesengrund in Frankfurt on 11 September 1903, the only child of Maria Calvelli-Adorno della Piana (1865–1952) and Oscar Alexander Wiesengrund (1870–1946). His mother, a Catholic from Corsica, was once a professional singer, while his father, an assimilated Jew who had converted to Protestantism, ran a successful wine-export business. His mother wanted her son's surname to include her own, Adorno. Thus, his earliest publications carried the name Theodor Wiesengrund-Adorno. Upon his application for US citizenship, his father's surname, Wiesengrund, was dropped from the name. His mother and aunt provided a vibrant musical life during his childhood. Maria was a singer who could boast of having performed in Vienna at the Imperial Court, while her sister, Agathe, who lived with them, had made a name for herself as both a singer and pianist. He was not only a precocious child but, as he recalled later in life, a child prodigy who could play pieces by Beethoven on the piano by the time he was twelve. At the age of six, he attended the Deutschherren Middle School before transferring to the Kaiser-Wilhelm Gymnasium, where he studied from 1913 to 1921. Before his graduation at the top of his class, Adorno was already swept up by the revolutionary mood of the time, as is evidenced by his reading of György Lukács's The Theory of the Novel that year, as well as by his fascination with Ernst Bloch's The Spirit of Utopia, of which he would later write:
Cell Centered Database – Astrocyte UIUC Histology Subject 57 "Astrocytes" Archived 2012-11-21 at the Wayback Machine at Society for Neuroscience The Department of Neuroscience at Wikiversity NIF Search – Astrocyte via the Neuroscience Information Framework
Sources: en.wikipedia.org
== Adverse effects == Mitragyna speciosa may cause many adverse effects, and in November 2017 the FDA issued a public health advisory for the drug. The side effects of kratom appear to be dose-dependent and are more common with doses that exceed 8 g. While the incidence of adverse effects in people who use kratom is unknown, a 2019 review of 935 kratom exposures reported to U.S. poison control centers over a seven-year period listed the following signs and symptoms: agitation (18.6%), tachycardia (16.9%), drowsiness (13.6%), vomiting (11.2%), confusion (8.1%), seizures (6.1%), withdrawal symptoms (6.1%), hallucinations (4.8%), respiratory depression (2.8%), coma (2.3%), and cardiac or respiratory arrest (0.6%). The study also reported two deaths and four cases of neonatal abstinence syndrome. A different 2019 review listed as common side effects: decreased appetite, weight loss, erectile dysfunction, insomnia, sweating, hyperpigmentation, hair loss, tremor, and constipation. Kratom products in the U.S. are commonly used in doses of 2–6 g of dried leaf, and doses exceeding 8 g are relatively uncommon. Given that kratom products may vary greatly in potency, there is no standard dosing system. At relatively low doses (1–5 g of raw leaves), at which there are mostly stimulant effects, side effects include contracted pupils and blushing; adverse effects related to stimulation include anxiety and agitation, and opioid-related effects such as itching, nausea, loss of appetite, and increased urination begin to appear.
Folk art in colonial America grew out of artisanal craftsmanship in communities that allowed commonly trained people to individually express themselves. It was distinct from Europe's tradition of high art, which was less accessible and generally less relevant to early American settlers. Cultural movements in art and craftsmanship in colonial America generally lagged behind those of Western Europe. For example, the prevailing medieval style of woodworking and primitive sculpture became integral to early American folk art, despite the emergence of Renaissance styles in England in the late 16th and early 17th centuries. The new English styles would have been early enough to make a considerable impact on American folk art, but American styles and forms had already been firmly adopted. Not only did styles change slowly in early America, but there was a tendency for rural artisans there to continue their traditional forms longer than their urban counterparts did—and far longer than those in Western Europe. The Hudson River School was a mid-19th-century movement in the visual arts tradition of European naturalism. The 1913 Armory Show in New York City, an exhibition of European modernist art, shocked the public and transformed the U.S. art scene. American Realism and American Regionalism sought to reflect and give America new ways of looking at itself. Georgia O'Keeffe, Marsden Hartley, and others experimented with new and individualistic styles, which would become known as American modernism.
To study the effect of various preparation of Testosterone on Steroid Profiling and Delta Value of 13C/12C of Testosterone Metabolite in volunteers with Normal/Abnormal Testosterone/ Epitestosterone (T/E) Ratio. Indian Herbal Drugs : Identification of stimulants, narcotics and other substances with potential of ergogenic aids in sports. Characterization of physiochemical properties and analysis of liposomes in human biological samples using hyphenated analytical technique. Detection of Stanozolol conjugated metabolites by liquid chromatography tandem-mass spectrometry. Prednisone excretion study and identification of its marker metabolites. Rapid determination of urinary phthalates using liquid chromatography tandem mass spectrometry. Identification of various banned small peptides in human urine using liquid chromatography tandem mass spectrometry.
Sources: en.wikipedia.org
Attributable: Documents are attributable to an individual Legible: They are readable Contemporaneously recorded: Not dated in the past (backdating) or the future (forward dating), but when the documented task is completed Original or a true copy: See also non-repudiation Accurate: Accurately reflecting the activity documented Permanent The products that are the subject of the GxP are expected to be
== S == Saegusa–Ito oxidation Sakurai reaction Salol reaction Sandheimer Sandmeyer diphenylurea isatin synthesis Sandmeyer isonitrosoacetanilide isatin synthesis Sandmeyer reaction Sanger reagent Saponification Sarett oxidation Schiemann reaction Schiff reaction Schiff test Schlenk equilibrium Schlosser modification Schlosser variant Schmidlin ketene synthesis Schmidt degradation Schmidt reaction Scholl reaction Schorigin Shorygin reaction, Shorygin reaction, Wanklyn reaction Schotten–Baumann reaction Seliwanoff's test Semidine rearrangement Semmler–Wolff reaction Seyferth–Gilbert homologation Shapiro reaction Sharpless asymmetric dihydroxylation Sharpless epoxidation Sharpless oxyamination or aminohydroxylation Shenck ene reaction Shi epoxidation Shiina esterification Shiina macrolactonization or Shiina lactonization Sigmatropic reaction Simmons–Smith reaction Simonini reaction Simonis chromone cyclization Simons process Skraup chinolin synthesis Skraup reaction Smiles rearrangement SNAr nucleophilic aromatic substitution SN1 SN2 SNi Solvolysis Sommelet reaction Sonn–Müller method Sonogashira coupling Sørensen formol titration Staedel–Rugheimer pyrazine synthesis Stahl oxidation Staudinger reaction Staudinger synthesis Steglich esterification Stephen aldehyde synthesis Stetter reaction Stevens rearrangement Stieglitz rearrangement Stille coupling Stobbe condensation Stollé synthesis Stork acylation Stork enamine alkylation Strecker amino acid synthesis Strecker degradation Strecker sulfite alkylation Strecker synthesis Stereocontrolled 1,2-addition to carbonyl groups Suzuki coupling Swain equation Swarts reaction Swern oxidation
==== Canada ==== On December 1, 2010, Health Canada and Paladin Labs Inc. announced the voluntary recall and withdrawal of Darvon-N from the Canadian market and the discontinuation of sale of Darvon-N.
== History == Several molecular biology studies during the early 1950s suggested that RNA played a role in protein synthesis, though the specific role remained unclear. For example, in one of the earliest reports, Ayaka Stephanie Hogg and his team showed that RNA synthesis was necessary for protein synthesis, specifically during the production of the enzyme β-galactosidase in the bacterium E. coli. Arthur Pardee also found similar RNA accumulation in 1954. In 1953, Alfred Hershey, June Dixon, and Martha Chase studied E. coli infected with bacteriophage T2 and reported that the bacterium's own DNA decreased while the phage's DNA built up inside the infected cells (including DNA containing 5-hydroxymethylcytosine). In hindsight, this has been discussed as part of the chain of observations that led to the concept of mRNA, and it was not recognized at the time as such. The idea of mRNA was first conceived by Sydney Brenner and Francis Crick on 15 April 1960 at King's College, Cambridge, while François Jacob was telling them about a recent experiment conducted by Arthur Pardee, himself, and Monod (the so-called PaJaMo experiment, which did not prove mRNA existed but suggested the possibility of its existence). With Crick's encouragement, Brenner and Jacob immediately set out to test this new hypothesis, and they contacted Matthew Meselson at the California Institute of Technology for assistance. During the summer of 1960, Brenner, Jacob, and Meselson conducted an experiment in Meselson's laboratory at Caltech which was the first to prove the existence of mRNA.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.